Gene therapy for renal diseases

Y. H. Lien, Li-Wen Lai

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Gene therapy is a promising therapeutic approach for a variety of renal diseases including both inherited and acquired diseases. In vivo gene transfer in the kidney using viral or non-viral vectors have been reported. These approaches have been tested in a few animal models of renal diseases, including experimental glomerulonephritis, ischemic renal failure, and carbonic anhydrase II deficiency. Selection of vectors, routes, and therapeutic genes is critical to the success of gene therapy targeted to the specific compartment of the kidney. Limitations of gene therapy for renal diseases exist and consist of: duration of transgene expression is short, transfection efficiency is not adequate, immune reactions are induced by adenoviral vector, and insertional mutagenesis may be caused by retroviral and adeno-associated vital vectors. Further studies are needed for improvement of gene delivery, minimization of side effects and development of cell-specific and long-term regulated gene expression.

Original languageEnglish (US)
JournalKidney International, Supplement
Volume51
Issue number61
StatePublished - 1997

Fingerprint

Genetic Therapy
Kidney
Genes
Animal Disease Models
Insertional Mutagenesis
Glomerulonephritis
Transgenes
Renal Insufficiency
Transfection
Gene Expression
Therapeutics

Keywords

  • Cell-specific gene expression
  • Drug delivery
  • Gene therapy
  • Liposome-mediated gene therapy

ASJC Scopus subject areas

  • Nephrology

Cite this

Gene therapy for renal diseases. / Lien, Y. H.; Lai, Li-Wen.

In: Kidney International, Supplement, Vol. 51, No. 61, 1997.

Research output: Contribution to journalArticle

@article{f06953ee9dac49e189a9e9fdec83d47f,
title = "Gene therapy for renal diseases",
abstract = "Gene therapy is a promising therapeutic approach for a variety of renal diseases including both inherited and acquired diseases. In vivo gene transfer in the kidney using viral or non-viral vectors have been reported. These approaches have been tested in a few animal models of renal diseases, including experimental glomerulonephritis, ischemic renal failure, and carbonic anhydrase II deficiency. Selection of vectors, routes, and therapeutic genes is critical to the success of gene therapy targeted to the specific compartment of the kidney. Limitations of gene therapy for renal diseases exist and consist of: duration of transgene expression is short, transfection efficiency is not adequate, immune reactions are induced by adenoviral vector, and insertional mutagenesis may be caused by retroviral and adeno-associated vital vectors. Further studies are needed for improvement of gene delivery, minimization of side effects and development of cell-specific and long-term regulated gene expression.",
keywords = "Cell-specific gene expression, Drug delivery, Gene therapy, Liposome-mediated gene therapy",
author = "Lien, {Y. H.} and Li-Wen Lai",
year = "1997",
language = "English (US)",
volume = "51",
journal = "Kidney International, Supplement",
issn = "0098-6577",
publisher = "Wiley-Blackwell",
number = "61",

}

TY - JOUR

T1 - Gene therapy for renal diseases

AU - Lien, Y. H.

AU - Lai, Li-Wen

PY - 1997

Y1 - 1997

N2 - Gene therapy is a promising therapeutic approach for a variety of renal diseases including both inherited and acquired diseases. In vivo gene transfer in the kidney using viral or non-viral vectors have been reported. These approaches have been tested in a few animal models of renal diseases, including experimental glomerulonephritis, ischemic renal failure, and carbonic anhydrase II deficiency. Selection of vectors, routes, and therapeutic genes is critical to the success of gene therapy targeted to the specific compartment of the kidney. Limitations of gene therapy for renal diseases exist and consist of: duration of transgene expression is short, transfection efficiency is not adequate, immune reactions are induced by adenoviral vector, and insertional mutagenesis may be caused by retroviral and adeno-associated vital vectors. Further studies are needed for improvement of gene delivery, minimization of side effects and development of cell-specific and long-term regulated gene expression.

AB - Gene therapy is a promising therapeutic approach for a variety of renal diseases including both inherited and acquired diseases. In vivo gene transfer in the kidney using viral or non-viral vectors have been reported. These approaches have been tested in a few animal models of renal diseases, including experimental glomerulonephritis, ischemic renal failure, and carbonic anhydrase II deficiency. Selection of vectors, routes, and therapeutic genes is critical to the success of gene therapy targeted to the specific compartment of the kidney. Limitations of gene therapy for renal diseases exist and consist of: duration of transgene expression is short, transfection efficiency is not adequate, immune reactions are induced by adenoviral vector, and insertional mutagenesis may be caused by retroviral and adeno-associated vital vectors. Further studies are needed for improvement of gene delivery, minimization of side effects and development of cell-specific and long-term regulated gene expression.

KW - Cell-specific gene expression

KW - Drug delivery

KW - Gene therapy

KW - Liposome-mediated gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0002431499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002431499&partnerID=8YFLogxK

M3 - Article

VL - 51

JO - Kidney International, Supplement

JF - Kidney International, Supplement

SN - 0098-6577

IS - 61

ER -